8:33 AM ET
8-K
Clinical Trial Data
Arcus Biosciences Clinical Trial Data
Arcus Biosciences presented new data from its ARC-20 platform study evaluating casdatifan in various treatment lines for clear cell renal cell carcinoma (ccRCC). Key results included a 50% confirmed objective response rate (cORR) for the first-line casdatifan plus zimberelimab combination and a 14.5-month median progression-free survival for the second-line combination with cabozantinib.